J Dermatol. 2001 Jun;28(6):299-302.
Stanozolol in chronic urticaria: a double blind, placebo controlled trial.
Parsad D, Pandhi R, Juneja A.
Department of Dermatology, Postgraduate Institute of Medical Education and
Research, Chandigarh, India.
H1-type antihistamine drugs are mainstays in the management of chronic urticaria.
For patients with refractory, chronic, idiopathic urticaria who have failed to
benefit from conventional therapy, other safe therapeutic modalities are
required. To evaluate the role of stanozolol as an adjunctive therapeutic agent
with H1-antihistamine in refractory chronic idiopathic urticaria, we conducted
this study. Fifty-eight patients with chronic refractory urticaria were enrolled
in this trial and were randomly assigned to two groups (A and B). Patients in
group A received 2 mg stanozolol twice daily along with cetrizine 10 mg daily.
Patients in group B received cetrizine 10 mg daily and placebo tablets twice
daily. The improvement was monitored by estimation of severity score. Of the 58
patients, 26 in group A and 24 in group B could be evaluated. At the end of 12
weeks, 17 patients in group A showed marked to complete resolution as compared to
7 patients in group B (chi-square p<0.01). The intention to treat analysis p
value was a found to be <0.007. There was a highly significant decrease in mean
severity score at 12 weeks (p<0.001) in group A patients. The present study
demonstrated that stanozolol is an effective and safe adjuvant therapy for
treatment of chronic refractory urticaria.
0 comments:
Post a Comment